

Clerk of the House of Representatives
Legislative Resource Center
B-106 Cannon Building
Washington, DC 20515

Secretary of the Senate
Office of Public Records
232 Hart Building
Washington, DC 20510

SECRETARY OF THE SENATE
OF THE

02 AUG 13 PM 4:18

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name The Waldmann Group			
2. Address <input type="checkbox"/> Check if different than previously reported 1201 Pennsylvania Ave., NW Suite 300, Washington, DC 20004			
3. Principal Place of Business (if different from line 2) City: _____ State/Zip (or Country) _____			
4. Contact Name Daniel R. Waldmann	Telephone (202) 661-4788	E-mail (optional)	5. Senate ID # 7003
7. Client Name <input type="checkbox"/> Self Johnson & Johnson			6. House ID # 35791

TYPE OF REPORT 8. Year 2002 Midyear (January 1-June 30) OR Year End (July 1-December 31)

9. Check if this filing amends a previously filed version of this report

10. Check if this is a Termination Report ⇨ Termination Date _____

11. No Lobbying

INCOME OR EXPENSES - Complete Either Line 12 OR Line 13

12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input checked="" type="checkbox"/> ⇨ \$ <u>40,000.00</u> <small>Income (nearest \$20,000)</small>	EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000 <input type="checkbox"/> \$10,000 or more <input type="checkbox"/> ⇨ \$ _____ <small>Expenses (nearest \$20,000)</small>
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client).	14. REPORTING METHOD. Check box to indicate accounting method. See instructions for description of <ul style="list-style-type: none"> <input type="checkbox"/> Method A. Reporting amounts using LDA definition <input type="checkbox"/> Method B. Reporting amounts under section 603 Internal Revenue Code <input type="checkbox"/> Method C. Reporting amounts under section 162 Internal Revenue Code

Signature

Daniel R. Waldmann

Printed Name and Title

Daniel R. Waldmann, Managing Director

Registrant Name The Waldmann Group Client Name Johnson & Johnson

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code HCR (one per page)

16. Specific lobbying issues

HR 3580, The Medical Device Amendments of 2001.
Reprocessing of single use medical devices.
Changes to the FDA generic drug approval process.
Reimportation of prescription drugs.
Direct to consumer (DTC) advertising of prescription drugs.
Protection from transmission of TSE/BSE through drugs and medical devices.
Reauthorization of the Prescription Drug User Fee Act (PDUFA) – HR 3448, Public Health Security and Bioterrorism Preparedness and Response Act of 2002.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives, Senate

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Daniel R. Waldmann	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Daniel R. Waldmann* Date 8-12-20
Printed Name and Title Daniel R. Waldmann

Registrant Name The Waldmann Group Client Name Johnson & Johnson

LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code information as requested. Attach additional page(s) as needed.

15. General issue area code MMM (one per page)

16. Specific lobbying issues

HR 4954, Medicare Modernization and Prescription Drug Act of 2002 -- Medicare reimbursement for medical devices and inpatient prescription drugs; Medicare coverage of outpatient prescription drugs.
Medicare coverage and reimbursement for self-injectable drugs.
Medicare reimbursement for drugs under the hospital outpatient prospective payment system.

17. House(s) of Congress and Federal agencies contacted Check if None

House of Representatives, Senate, Centers for Medicare and Medicaid Services (CMS)

18. Name of each individual who acted as a lobbyist in this issue area

Name	Covered Official Position (if applicable)
Daniel R. Waldmann	

19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None

Signature *Daniel R. Waldmann* Date 8-12-200

Printed Name and Title Daniel R. Waldmann, Managing Director

